Alphatec (NASDAQ:ATEC) Director David Pelizzon Sells 250,000 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) Director David Pelizzon sold 250,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $20.80, for a total value of $5,200,000.00. Following the completion of the sale, the director directly owned 11,145,045 shares of the company’s stock, valued at approximately $231,816,936. This trade represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alphatec Stock Performance

ATEC traded down $0.46 during trading on Friday, hitting $19.74. 2,603,589 shares of the stock were exchanged, compared to its average volume of 2,130,456. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a 1-year low of $8.18 and a 1-year high of $21.16. The stock has a fifty day moving average price of $15.99 and a two-hundred day moving average price of $13.82. The firm has a market capitalization of $2.93 billion, a P/E ratio of -17.47 and a beta of 1.17.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to analysts’ expectations of $182.78 million. The business’s revenue was up 30.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.28) earnings per share. Alphatec has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd acquired a new stake in Alphatec in the third quarter valued at $34,000. Osterweis Capital Management Inc. purchased a new position in shares of Alphatec in the 2nd quarter valued at about $37,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Alphatec in the third quarter valued at about $73,000. Larson Financial Group LLC purchased a new stake in Alphatec during the first quarter worth about $54,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock worth $63,000 after buying an additional 1,045 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ATEC. Piper Sandler restated an “overweight” rating and issued a $25.00 price objective (up from $20.00) on shares of Alphatec in a research note on Friday, October 31st. JPMorgan Chase & Co. assumed coverage on Alphatec in a research report on Friday, October 24th. They issued an “overweight” rating and a $19.00 price target on the stock. Barclays upped their price objective on Alphatec from $22.00 to $23.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. HC Wainwright lifted their target price on Alphatec from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Morgan Stanley upped their price target on Alphatec from $16.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Monday. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.00.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.